<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35397615</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2158-3188</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>Translational psychiatry</Title>
          <ISOAbbreviation>Transl Psychiatry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cerebrospinal fluid catecholamines in Alzheimer's disease patients with and without biological disease.</ArticleTitle>
        <Pagination>
          <StartPage>151</StartPage>
          <MedlinePgn>151</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">151</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41398-022-01901-5</ELocationID>
        <Abstract>
          <AbstractText>Noradrenergic and dopaminergic neurons are involved in cognitive functions, relate to behavioral and psychological symptoms in dementia and are affected in Alzheimer's disease (AD). Amyloid plaques (A), neurofibrillary tangles (T) and neurodegeneration (N) hallmarks the AD neuropathology. Today, the AT(N) pathophysiology can be assessed through biomarkers. Previous studies report cerebrospinal fluid (CSF) catecholamine concentrations in AD patients without biomarker refinement. We explored if CSF catecholamines relate to AD clinical presentation or neuropathology as reflected by CSF biomarkers. CSF catecholamines were analyzed in AD patients at the mild cognitive impairment (MCI; n = 54) or dementia stage (n = 240) and in cognitively unimpaired (n = 113). CSF biomarkers determined AT status and indicated synaptic damage (neurogranin). The AD patients (n = 294) had higher CSF noradrenaline and adrenaline concentrations, but lower dopamine concentrations compared to the cognitively unimpaired (n = 113). AD patients in the MCI and dementia stage of the disease had similar CSF catecholamine concentrations. In the CSF neurogranin positively associated with noradrenaline and adrenaline but not with dopamine. Adjusted regression analyses including AT status, CSF neurogranin, age, gender, and APOEε4 status verified the findings. In restricted analyses comparing A+T+ patients to A-T- cognitively unimpaired, the findings for CSF adrenaline remained significant (p &lt; 0.001) but not for CSF noradrenaline (p = 0.07) and CSF dopamine (p = 0.33). There were no differences between A+T+ and A-T- cognitively unimpaired. Thus, we find alterations in CSF catecholamines in symptomatic AD and the CSF adrenergic transmitters to increase simultaneously with synaptic damage as indexed by CSF neurogranin.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Henjum</LastName>
            <ForeName>Kristi</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0001-9147-7282</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Geriatric Medicine, Institute of Clinical Medicine, Oslo University Hospital, Ullevaal, University of Oslo, Oslo, Norway. Kristi.henjum@medisin.uio.no.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Geriatric Medicine, Oslo University Hospital, Ullevaal, Oslo, Oslo, Nydalen, Norway. Kristi.henjum@medisin.uio.no.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Watne</LastName>
            <ForeName>Leiv Otto</ForeName>
            <Initials>LO</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Geriatric Medicine, Oslo University Hospital, Ullevaal, Oslo, Oslo, Nydalen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Godang</LastName>
            <ForeName>Kristin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Halaas</LastName>
            <ForeName>Nathalie Bodd</ForeName>
            <Initials>NB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Geriatric Medicine, Institute of Clinical Medicine, Oslo University Hospital, Ullevaal, University of Oslo, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Geriatric Medicine, Oslo University Hospital, Ullevaal, Oslo, Oslo, Nydalen, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eldholm</LastName>
            <ForeName>Rannveig Saksholm</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Geriatrics, St. Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blennow</LastName>
            <ForeName>Kaj</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-1890-4193</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zetterberg</LastName>
            <ForeName>Henrik</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-3930-4354</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saltvedt</LastName>
            <ForeName>Ingvild</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-7897-9808</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Geriatrics, St. Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bollerslev</LastName>
            <ForeName>Jens</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, University of Oslo, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Knapskog</LastName>
            <ForeName>Anne Brita</ForeName>
            <Initials>AB</Initials>
            <Identifier Source="ORCID">0000-0003-4867-551X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Geriatric Medicine, Oslo University Hospital, Ullevaal, Oslo, Oslo, Nydalen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Transl Psychiatry</MedlineTA>
        <NlmUniqueID>101562664</NlmUniqueID>
        <ISSNLinking>2158-3188</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002395">Catecholamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>132654-77-4</RegistryNumber>
          <NameOfSubstance UI="D051579">Neurogranin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>VTD58H1Z2X</RegistryNumber>
          <NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>X4W3ENH1CV</RegistryNumber>
          <NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YKH834O4BH</RegistryNumber>
          <NameOfSubstance UI="D004837">Epinephrine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName>
          <QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
          <QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002395" MajorTopicYN="N">Catecholamines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004837" MajorTopicYN="N">Epinephrine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051579" MajorTopicYN="N">Neurogranin</DescriptorName>
          <QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName>
          <QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName>
          <QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>ABK has been/is a principal investigator in Roche drug trials BN29553 and Novo Nordisk, NN6535-4730, and ABK and IS in Boehringer-Ingelheim drug trial 1346.0023. IS has been a consultant at the advisory board for Biogen. K.B. has worked as a consultant or at advisory boards or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. H.Z. has served at scientific advisory boards for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, and CogRx, and has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen. KB and HZ are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. The other authors have no conflicts of interest to report.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>20</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35397615</ArticleId>
        <ArticleId IdType="pmc">PMC8994756</ArticleId>
        <ArticleId IdType="doi">10.1038/s41398-022-01901-5</ArticleId>
        <ArticleId IdType="pii">10.1038/s41398-022-01901-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s Dement. 2013;9:63–75.e62. doi: 10.1016/j.jalz.2012.11.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2012.11.007</ArticleId>
            <ArticleId IdType="pubmed">23305823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al.  National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimer’s Dement. 2012;8:1–13. doi: 10.1016/j.jalz.2011.10.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId>
            <ArticleId IdType="pmc">PMC3266529</ArticleId>
            <ArticleId IdType="pubmed">22265587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trillo L, Das D, Hsieh W, Medina B, Moghadam S, Lin B, et al.  Ascending monoaminergic systems alterations in Alzheimer’s disease. translating basic science into clinical care. Neurosci Biobehav Rev. 2013;37:1363–79. doi: 10.1016/j.neubiorev.2013.05.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neubiorev.2013.05.008</ArticleId>
            <ArticleId IdType="pubmed">23707776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Šimić G, Babić Leko M, Wray S, Harrington CR, Delalle I, Jovanov-Milošević N, et al.  Monoaminergic neuropathology in Alzheimer’s disease. Prog Neurobiol. 2017;151:101–38. doi: 10.1016/j.pneurobio.2016.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pneurobio.2016.04.001</ArticleId>
            <ArticleId IdType="pmc">PMC5061605</ArticleId>
            <ArticleId IdType="pubmed">27084356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szabadi E. Functional neuroanatomy of the central noradrenergic system. J Psychopharmacol. 2013;27:659–93. doi: 10.1177/0269881113490326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0269881113490326</ArticleId>
            <ArticleId IdType="pubmed">23761387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robbins TW, Arnsten AF. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci. 2009;32:267–87. doi: 10.1146/annurev.neuro.051508.135535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.neuro.051508.135535</ArticleId>
            <ArticleId IdType="pmc">PMC2863127</ArticleId>
            <ArticleId IdType="pubmed">19555290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci. 2009;10:211–23. doi: 10.1038/nrn2573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn2573</ArticleId>
            <ArticleId IdType="pubmed">19190638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer’s disease. Nat Immunol. 2015;16:229–36. doi: 10.1038/ni.3102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3102</ArticleId>
            <ArticleId IdType="pubmed">25689443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, et al.  Locus ceruleus controls Alzheimer’s disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci USA. 2010;107:6058–63. doi: 10.1073/pnas.0909586107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0909586107</ArticleId>
            <ArticleId IdType="pmc">PMC2851853</ArticleId>
            <ArticleId IdType="pubmed">20231476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matchett BJ, Grinberg LT, Theofilas P, Murray ME. The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer’s disease. Acta Neuropathol. 2021;141:631–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8043919</ArticleId>
            <ArticleId IdType="pubmed">33427939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60:337–41. doi: 10.1001/archneur.60.3.337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.60.3.337</ArticleId>
            <ArticleId IdType="pubmed">12633144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960–9. doi: 10.1097/NEN.0b013e318232a379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId>
            <ArticleId IdType="pubmed">22002422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pletnikova O, Kageyama Y, Rudow G, LaClair KD, Albert M, Crain BJ, et al.  The spectrum of preclinical Alzheimer’s disease pathology and its modulation by ApoE genotype. Neurobiol Aging. 2018;71:72–80. doi: 10.1016/j.neurobiolaging.2018.07.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.07.007</ArticleId>
            <ArticleId IdType="pubmed">30099348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arendt T, Brückner MK, Morawski M, Jäger C, Gertz HJ. Early neurone loss in Alzheimer’s disease: cortical or subcortical? Acta Neuropathol Commun. 2015;3:10. doi: 10.1186/s40478-015-0187-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40478-015-0187-1</ArticleId>
            <ArticleId IdType="pmc">PMC4359478</ArticleId>
            <ArticleId IdType="pubmed">25853173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theofilas P, Ehrenberg AJ, Dunlop S, Di Lorenzo Alho AT, Nguy A, Leite REP, et al.  Locus coeruleus volume and cell population changes during Alzheimer’s disease progression: a stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimer’s Dement. 2017;13:236–46. doi: 10.1016/j.jalz.2016.06.2362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2016.06.2362</ArticleId>
            <ArticleId IdType="pmc">PMC5298942</ArticleId>
            <ArticleId IdType="pubmed">27513978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly SC, He B, Perez SE, Ginsberg SD, Mufson EJ, Counts SE. Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease. Acta Neuropathol Commun. 2017;5:8. doi: 10.1186/s40478-017-0411-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40478-017-0411-2</ArticleId>
            <ArticleId IdType="pmc">PMC5251221</ArticleId>
            <ArticleId IdType="pubmed">28109312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrés-Benito P, Fernández-Dueñas V, Carmona M, Escobar LA, Torrejón-Escribano B, Aso E, et al.  Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology. Neuropathol Appl Neurobiol. 2017;43:373–92. doi: 10.1111/nan.12386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nan.12386</ArticleId>
            <ArticleId IdType="pubmed">28117912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guyenet PG, Stornetta RL, Bochorishvili G, Depuy SD, Burke PG, Abbott SB. C1 neurons: the body’s EMTs. Am J Physiol Regul Integr Comp Physiol. 2013;305:R187–204. doi: 10.1152/ajpregu.00054.2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpregu.00054.2013</ArticleId>
            <ArticleId IdType="pmc">PMC3743001</ArticleId>
            <ArticleId IdType="pubmed">23697799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Amelio M, Puglisi-Allegra S, Mercuri N. The role of dopaminergic midbrain in Alzheimer’s disease: translating basic science into clinical practice. Pharm Res. 2018;130:414–9. doi: 10.1016/j.phrs.2018.01.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2018.01.016</ArticleId>
            <ArticleId IdType="pubmed">29391234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibb WR, Mountjoy CQ, Mann DM, Lees AJ. The substantia nigra and ventral tegmental area in Alzheimer’s disease and Down’s syndrome. J Neurol Neurosurg Psychiatry. 1989;52:193–200. doi: 10.1136/jnnp.52.2.193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.52.2.193</ArticleId>
            <ArticleId IdType="pmc">PMC1032505</ArticleId>
            <ArticleId IdType="pubmed">2539435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colloby SJ, McParland S, O’Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain. 2012;135:2798–808. doi: 10.1093/brain/aws211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aws211</ArticleId>
            <ArticleId IdType="pubmed">22961551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyagawa T, Przybelski SA, Maltais D, Min HK, Jordan L, Lesnick TG, et al.  The value of multimodal imaging with (123)I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer’s disease dementia. Neurobiol Aging. 2021;99:11–18. doi: 10.1016/j.neurobiolaging.2020.12.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.12.009</ArticleId>
            <ArticleId IdType="pmc">PMC7902470</ArticleId>
            <ArticleId IdType="pubmed">33422890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nobili A, Latagliata EC, Viscomi MT, Cavallucci V, Cutuli D, Giacovazzo G, et al.  Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer’s disease. Nat Commun. 2017;8:14727. doi: 10.1038/ncomms14727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms14727</ArticleId>
            <ArticleId IdType="pmc">PMC5382255</ArticleId>
            <ArticleId IdType="pubmed">28367951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Marco M, Venneri A. Volume and connectivity of the ventral tegmental area are linked to neurocognitive signatures of Alzheimer’s disease in humans. J Alzheimers Dis. 2018;63:167–80. doi: 10.3233/JAD-171018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-171018</ArticleId>
            <ArticleId IdType="pubmed">29578486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al.  A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–47. doi: 10.1212/WNL.0000000000002923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002923</ArticleId>
            <ArticleId IdType="pmc">PMC4970664</ArticleId>
            <ArticleId IdType="pubmed">27371494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al.  NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14:535–62. doi: 10.1016/j.jalz.2018.02.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId>
            <ArticleId IdType="pmc">PMC5958625</ArticleId>
            <ArticleId IdType="pubmed">29653606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pak JH, Huang FL, Li J, Balschun D, Reymann KG, Chiang C, et al.  Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice. Proc Natl Acad Sci USA. 2000;97:11232–7. doi: 10.1073/pnas.210184697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.210184697</ArticleId>
            <ArticleId IdType="pmc">PMC17183</ArticleId>
            <ArticleId IdType="pubmed">11016969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Represa A, Deloulme JC, Sensenbrenner M, Ben-Ari Y, Baudier J. Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci. 1990;10:3782–92. doi: 10.1523/JNEUROSCI.10-12-03782.1990.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.10-12-03782.1990</ArticleId>
            <ArticleId IdType="pmc">PMC6570038</ArticleId>
            <ArticleId IdType="pubmed">2269883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Portelius E, Olsson B, Hoglund K, Cullen NC, Kvartsberg H, Andreasson U, et al.  Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136:363–76. doi: 10.1007/s00401-018-1851-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-018-1851-x</ArticleId>
            <ArticleId IdType="pmc">PMC6096740</ArticleId>
            <ArticleId IdType="pubmed">29700597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wellington H, Paterson RW, Portelius E, Törnqvist U, Magdalinou N, Fox NC, et al.  Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86:829–35. doi: 10.1212/WNL.0000000000002423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002423</ArticleId>
            <ArticleId IdType="pmc">PMC4793782</ArticleId>
            <ArticleId IdType="pubmed">26826204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogdanovic N, Davidsson P, Gottfries J, Volkman I, Winblad B, Blennow K. Regional and cellular distribution of synaptic proteins in the normal human brain. Brain Aging. 2002;2:18–30.</Citation>
        </Reference>
        <Reference>
          <Citation>Raskind MA, Peskind ER, Halter JB, Jimerson DC. Norepinephrine and MHPG levels in CSF and plasma in Alzheimer’s disease. Arch Gen Psychiatry. 1984;41:343–6. doi: 10.1001/archpsyc.1984.01790150033006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archpsyc.1984.01790150033006</ArticleId>
            <ArticleId IdType="pubmed">6703854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parnetti L, Gaiti A, Reboldi GP, Santucci C, Mecocci P, Brunetti M, et al.  CSF monoamine metabolites in old age dementias. Mol Chem Neuropathol. 1992;16:143–57. doi: 10.1007/BF03159966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03159966</ArticleId>
            <ArticleId IdType="pubmed">1381590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elrod R, Peskind ER, DiGiacomo L, Brodkin KI, Veith RC, Raskind MA. Effects of Alzheimer’s disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiatry. 1997;154:25–30. doi: 10.1176/ajp.154.1.25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ajp.154.1.25</ArticleId>
            <ArticleId IdType="pubmed">8988954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stefani A, Olivola E, Liguori C, Hainsworth AH, Saviozzi V, Angileri G, et al.  Catecholamine-based treatment in AD patients: expectations and delusions. Front Aging Neurosci. 2015;7:67. doi: 10.3389/fnagi.2015.00067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2015.00067</ArticleId>
            <ArticleId IdType="pmc">PMC4418272</ArticleId>
            <ArticleId IdType="pubmed">25999852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peskind ER, Elrod R, Dobie DJ, Pascualy M, Petrie E, Jensen C, et al.  Cerebrospinal fluid epinephrine in Alzheimer’s disease and normal aging. Neuropsychopharmacology. 1998;19:465–71. doi: 10.1016/S0893-133X(98)00054-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0893-133X(98)00054-2</ArticleId>
            <ArticleId IdType="pubmed">9803422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blennow K, Wallin A, Gottfries CG, Lekman A, Karlsson I, Skoog I, et al.  Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer’s disease. Neurobiol Aging. 1992;13:107–13. doi: 10.1016/0197-4580(92)90017-R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0197-4580(92)90017-R</ArticleId>
            <ArticleId IdType="pubmed">1371850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol. 1990;27:457–64. doi: 10.1002/ana.410270502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410270502</ArticleId>
            <ArticleId IdType="pubmed">2360787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9. doi: 10.1016/j.jalz.2011.03.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2011.03.008</ArticleId>
            <ArticleId IdType="pmc">PMC3312027</ArticleId>
            <ArticleId IdType="pubmed">21514249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al.  The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. doi: 10.1016/j.jalz.2011.03.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId>
            <ArticleId IdType="pmc">PMC3312024</ArticleId>
            <ArticleId IdType="pubmed">21514250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brækhus A, Ulstein I, Wyller TB, Engedal K. The Memory Clinic—outpatient assessment when dementia is suspected. Tidsskr Nor Laegeforen. 2011;131:2254–7. doi: 10.4045/tidsskr.11.0786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4045/tidsskr.11.0786</ArticleId>
            <ArticleId IdType="pubmed">22085955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26:231–45. doi: 10.1007/BF02815140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02815140</ArticleId>
            <ArticleId IdType="pubmed">8748926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanderstichele H, Van KE, Hesse C, Davidsson P, Buyse MA, Andreasen N, et al.  Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid. 2000;7:245–58. doi: 10.3109/13506120009146438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/13506120009146438</ArticleId>
            <ArticleId IdType="pubmed">11132093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56:673–80. doi: 10.1001/archneur.56.6.673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.56.6.673</ArticleId>
            <ArticleId IdType="pubmed">10369305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Idland AV, Sala-Llonch R, Borza T, Watne LO, Wyller TB, Braekhus A, et al.  CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. Neurobiol Aging. 2017;49:138–44. doi: 10.1016/j.neurobiolaging.2016.09.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.09.012</ArticleId>
            <ArticleId IdType="pubmed">27794264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228–34. doi: 10.1016/S1474-4422(06)70355-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(06)70355-6</ArticleId>
            <ArticleId IdType="pubmed">16488378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henjum K, Godang K, Quist-Paulsen E, Idland A-V, Neerland BE, Sandvig H, et al. Cerebrospinal fluid catecholamines in delirium and dementia. Brain Commun. 2021;3:fcab121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8374970</ArticleId>
            <ArticleId IdType="pubmed">34423298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, et al.  Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol. 2015;72:1275–80. doi: 10.1001/jamaneurol.2015.1867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2015.1867</ArticleId>
            <ArticleId IdType="pmc">PMC4694558</ArticleId>
            <ArticleId IdType="pubmed">26366630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abbott SB, Kanbar R, Bochorishvili G, Coates MB, Stornetta RL, Guyenet PG. C1 neurons excite locus coeruleus and A5 noradrenergic neurons along with sympathetic outflow in rats. J Physiol. 2012;590:2897–915. doi: 10.1113/jphysiol.2012.232157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.2012.232157</ArticleId>
            <ArticleId IdType="pmc">PMC3448155</ArticleId>
            <ArticleId IdType="pubmed">22526887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holloway BB, Stornetta RL, Bochorishvili G, Erisir A, Viar KE, Guyenet PG. Monosynaptic glutamatergic activation of locus coeruleus and other lower brainstem noradrenergic neurons by the C1 cells in mice. J Neurosci. 2013;33:18792–805. doi: 10.1523/JNEUROSCI.2916-13.2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.2916-13.2013</ArticleId>
            <ArticleId IdType="pmc">PMC3841449</ArticleId>
            <ArticleId IdType="pubmed">24285886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raskind MA, Peskind ER, Holmes C, Goldstein DS. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer’s disease. Biol Psychiatry. 1999;46:756–65. doi: 10.1016/S0006-3223(99)00008-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-3223(99)00008-6</ArticleId>
            <ArticleId IdType="pubmed">10494443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, et al.  Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls. Alzheimers Res Ther. 2015;7:40. doi: 10.1186/s13195-015-0124-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13195-015-0124-3</ArticleId>
            <ArticleId IdType="pmc">PMC4487851</ArticleId>
            <ArticleId IdType="pubmed">26136856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braak H, Del Tredici K. Where, when, and in what form does sporadic Alzheimer’s disease begin? Curr Opin Neurol. 2012;25:708–14. doi: 10.1097/WCO.0b013e32835a3432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0b013e32835a3432</ArticleId>
            <ArticleId IdType="pubmed">23160422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer’s disease and dementia with Lewy bodies. J Neurosci. 2006;26:467–78. doi: 10.1523/JNEUROSCI.4265-05.2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.4265-05.2006</ArticleId>
            <ArticleId IdType="pmc">PMC6674412</ArticleId>
            <ArticleId IdType="pubmed">16407544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoogendijk WJ, Feenstra MG, Botterblom MH, Gilhuis J, Sommer IE, Kamphorst W, et al.  Increased activity of surviving locus ceruleus neurons in Alzheimer’s disease. Ann Neurol. 1999;45:82–91. doi: 10.1002/1531-8249(199901)45:1&lt;82::AID-ART14&gt;3.0.CO;2-T.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(199901)45:1&lt;82::AID-ART14&gt;3.0.CO;2-T</ArticleId>
            <ArticleId IdType="pubmed">9894881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobs HIL, Riphagen JM, Ramakers I, Verhey FRJ. Alzheimer’s disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms. Mol Psychiatry. 2019;26:897–906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31138892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stern Y. Cognitive reserve. Neuropsychologia. 2009;47:2015–28. doi: 10.1016/j.neuropsychologia.2009.03.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropsychologia.2009.03.004</ArticleId>
            <ArticleId IdType="pmc">PMC2739591</ArticleId>
            <ArticleId IdType="pubmed">19467352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janssens J, Vermeiren Y, Fransen E, Aerts T, Van Dam D, Engelborghs S, et al.  Cerebrospinal fluid and serum MHPG improve Alzheimer’s disease versus dementia with Lewy bodies differential diagnosis. Alzheimer’s Dement. 2018;10:172–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5852321</ArticleId>
            <ArticleId IdType="pubmed">29552632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi J, Shibata T, Sasaki M, Kudo M, Yanezawa H, Obara S, et al.  Detection of changes in the locus coeruleus in patients with mild cognitive impairment and Alzheimer’s disease: high-resolution fast spin-echo T1-weighted imaging. Geriatr Gerontol Int. 2015;15:334–40. doi: 10.1111/ggi.12280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ggi.12280</ArticleId>
            <ArticleId IdType="pmc">PMC4405055</ArticleId>
            <ArticleId IdType="pubmed">24661561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janssens J, Atmosoerodjo SD, Vermeiren Y, Absalom AR, den Daas I, De Deyn PP. Sampling issues of cerebrospinal fluid and plasma monoamines: investigation of the circadian rhythm and rostrocaudal concentration gradient. Neurochem Int. 2019;128:154–62. doi: 10.1016/j.neuint.2019.04.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuint.2019.04.015</ArticleId>
            <ArticleId IdType="pubmed">31034914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pillet LE, Taccola C, Cotoni J, Thiriez H, André K, Verpillot R. Correlation between cognition and plasma noradrenaline level in Alzheimer’s disease: a potential new blood marker of disease evolution. Transl psychiatry. 2020;10:213. doi: 10.1038/s41398-020-0841-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41398-020-0841-7</ArticleId>
            <ArticleId IdType="pmc">PMC7335170</ArticleId>
            <ArticleId IdType="pubmed">32620743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adolfsson R, Gottfries CG, Roos BE, Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry. 1979;135:216–23. doi: 10.1192/bjp.135.3.216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1192/bjp.135.3.216</ArticleId>
            <ArticleId IdType="pubmed">486847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sjögren M, Minthon L, Passant U, Blennow K, Wallin A. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer’s disease. Neurobiol Aging. 1998;19:379–84. doi: 10.1016/S0197-4580(98)00086-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0197-4580(98)00086-4</ArticleId>
            <ArticleId IdType="pubmed">9880039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al.  Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403–13. doi: 10.1002/ana.21610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21610</ArticleId>
            <ArticleId IdType="pmc">PMC2696350</ArticleId>
            <ArticleId IdType="pubmed">19296504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Improved discrimination of autopsy-confirmed Alzheimer’s disease (AD) from non-AD dementias using CSF P-tau(181P) Neurochem Int. 2009;55:214–8. doi: 10.1016/j.neuint.2009.02.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuint.2009.02.017</ArticleId>
            <ArticleId IdType="pubmed">19524111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 2010;119:421–33. doi: 10.1007/s00401-010-0654-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-010-0654-5</ArticleId>
            <ArticleId IdType="pubmed">20204386</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
